Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$620,000 |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$381M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$30,000 |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Azamian Bobak R. | Mar 24, 2025 | Sell | 6,000 | $50 | $300,000 |
| Mottiwala Aziz | Mar 20, 2025 | Sell | 3,365 | $50.11 | $170,000 |
| Neervannan Seshadri | Mar 20, 2025 | Sell | 2,435 | $50.11 | $120,000 |
| Wahl Bryan | Mar 20, 2025 | Sell | 3,084 | $50.11 | $150,000 |
| Whitfield Dianne C. | Mar 20, 2025 | Sell | 2,137 | $50.11 | $110,000 |
| Azamian Bobak R. | Mar 20, 2025 | Sell | 8,534 | $50.11 | $430,000 |
| Farrow Jeffrey S | Mar 20, 2025 | Sell | 1,186 | $50.11 | $59,000 |
| Mottiwala Aziz | Mar 19, 2025 | Sell | 3,557 | $47.4 | $170,000 |
| Neervannan Seshadri | Mar 19, 2025 | Sell | 2,543 | $47.4 | $120,000 |
| Wahl Bryan | Mar 19, 2025 | Sell | 3,261 | $47.4 | $150,000 |
| Whitfield Dianne C. | Mar 19, 2025 | Sell | 2,259 | $47.4 | $110,000 |
| Azamian Bobak R. | Mar 19, 2025 | Sell | 8,551 | $47.4 | $410,000 |
| Farrow Jeffrey S | Mar 19, 2025 | Sell | 1,254 | $47.4 | $59,000 |
| Mottiwala Aziz | Mar 18, 2025 | Sell | 3,643 | $46.29 | $170,000 |
| Neervannan Seshadri | Mar 18, 2025 | Sell | 2,605 | $46.29 | $120,000 |
| Wahl Bryan | Mar 18, 2025 | Sell | 3,341 | $46.29 | $150,000 |
| Whitfield Dianne C. | Mar 18, 2025 | Sell | 2,315 | $46.29 | $110,000 |
| Azamian Bobak R. | Mar 18, 2025 | Sell | 7,131 | $46.29 | $330,000 |
| Farrow Jeffrey S | Mar 18, 2025 | Sell | 1,284 | $46.29 | $59,000 |
| LINK WILLIAM J PHD | Aug 12, 2024 | Sell | 29,979 | $26.01 | $780,000 |
| LINK WILLIAM J PHD | Aug 12, 2024 | Sell | 5,021 | $26.53 | $130,000 |
| Farrow Jeffrey S | Jun 18, 2024 | Sell | 10,445 | $27.47 | $290,000 |
| Azamian Bobak R. | Mar 18, 2024 | Sell | 10,415 | $30.6 | $320,000 |
| Mottiwala Aziz | Mar 18, 2024 | Sell | 4,766 | $30.6 | $150,000 |
| Wahl Bryan | Mar 18, 2024 | Sell | 4,436 | $30.6 | $140,000 |
| Whitfield Dianne C. | Mar 18, 2024 | Sell | 4,314 | $30.6 | $130,000 |
| Neervannan Seshadri | Mar 18, 2024 | Sell | 4,879 | $30.6 | $150,000 |
| Azamian Bobak R. | Dec 27, 2023 | Sell | 8,000 | $20.22 | $160,000 |
| Azamian Bobak R. | Dec 20, 2023 | Sell | 30,557 | $20.36 | $620,000 |
| Azamian Bobak R. | Dec 20, 2023 | Sell | 9,443 | $19.96 | $190,000 |
| Trevejo Jose M. | Dec 20, 2023 | Sell | 2,252 | $20 | $45,000 |
| Goldberg Andrew D. | Dec 15, 2023 | Buy | 1,000 | $18.96 | $19,000 |
| Wahl Bryan | Nov 30, 2023 | Sell | 8,356 | $16.31 | $140,000 |
| Whitfield Dianne C. | Nov 30, 2023 | Sell | 8,355 | $16.31 | $140,000 |
| Azamian Bobak R. | Nov 15, 2023 | Sell | 4,904 | $18.54 | $91,000 |
| Azamian Bobak R. | Nov 15, 2023 | Sell | 2,896 | $18.01 | $52,000 |
| Azamian Bobak R. | Nov 15, 2023 | Sell | 200 | $19.28 | $3,900 |
| Azamian Bobak R. | Oct 18, 2023 | Sell | 8,000 | $13.24 | $110,000 |
| Trevejo Jose M. | Oct 5, 2023 | Sell | 1,604 | $18 | $29,000 |
| Azamian Bobak R. | Sep 20, 2023 | Sell | 8,000 | $17.21 | $140,000 |
| Azamian Bobak R. | Aug 23, 2023 | Sell | 8,000 | $17.23 | $140,000 |
| Lin Elizabeth Yeu | Aug 15, 2023 | Buy | 9,506 | $16.8 | $160,000 |
| Azamian Bobak R. | Jul 19, 2023 | Sell | 99,726 | $20.04 | $2M |
| Azamian Bobak R. | Jul 19, 2023 | Sell | 4,174 | $19.28 | $80,000 |
| Mottiwala Aziz | Jul 19, 2023 | Sell | 2,400 | $20.05 | $48,000 |
| Azamian Bobak R. | Jul 12, 2023 | Sell | 9,000 | $17.35 | $160,000 |
| Azamian Bobak R. | Jun 21, 2023 | Sell | 8,000 | $18.63 | $150,000 |
| Azamian Bobak R. | Jun 14, 2023 | Sell | 9,000 | $18.58 | $170,000 |
| Azamian Bobak R. | Jun 8, 2023 | Sell | 3,100 | $20.01 | $62,000 |
| Mottiwala Aziz | Jun 8, 2023 | Sell | 100 | $20 | $2,000 |
| Mottiwala Aziz | Jun 7, 2023 | Sell | 2,500 | $19.34 | $48,000 |
| Mottiwala Aziz | Jun 6, 2023 | Sell | 2,143 | $18.61 | $40,000 |
| Azamian Bobak R. | May 17, 2023 | Sell | 8,000 | $15.9 | $130,000 |
| Azamian Bobak R. | May 10, 2023 | Sell | 9,000 | $16.8 | $150,000 |
What's the latest insider transaction for Tarsus Pharmaceuticals?
The most recent insider transaction for Tarsus Pharmaceuticals was conducted by Azamian Bobak R., who sold 6,000 shares on March 24, 2025 at a price of $50.00 per share.
Which insider bought the most TARS stock over the last two years?
Lin Elizabeth Yeu has bought the most TARS stock in the last 2 years, with a total value of $160,000.
Which insider has sold the most TARS stock over the last two years?
Azamian Bobak R. has sold the most TARS stock in the last 2 years, with a total value of $6.2M.
What is the total value of insider transactions for Tarsus Pharmaceuticals (TARS) in the last 2 years?
The total value of insider transactions for Tarsus Pharmaceuticals in the last 2 years is negative, amounting to -$10M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Tarsus Pharmaceuticals' market confidence?
Over the last 2 years, insider transactions for Tarsus Pharmaceuticals have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
